Anzalone Nicoletta, Scotti Roberta, Iadanza Antonella
Department of Neuroradiology, S. Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.
Neuroradiology. 2006 Apr;48 Suppl 1:9-17. doi: 10.1007/s00234-006-1464-2.
Several studies have shown the usefulness of contrast-enhanced MR angiography (CE-MRA) for imaging the supraortic vessels, and, as a consequence, it has rapidly become a routine imaging modality. The main advantage over unenhanced techniques is the possibility to acquire larger volumes, allowing demonstration of the carotid artery from its origin to the intracranial portion. Most published studies on CE-MRA of the carotid arteries have been performed with standard Gd-based chelates whose T1 relaxivity values are similar. Recently new gadolinium chelates such as gadobenate dimeglumine (Gd-BOP-TA, MultiHance; Bracco Imaging, Milan, Italy) have been developed which have markedly higher intravascular T1 relaxivity values. When administered at an equivalent dose to that of a standard agent, these newer contrast agents produce significantly greater intravascular signal enhancement. The availability of an appropriate high-relaxivity contrast agent might also help to overcome some of the intrinsic technical problems (e. g. those related to flow) that affect time-of-flight (TOF) and phase contrast (PC) MR angiography of the intracranial vasculature. To avoid the problem of superimposition of veins, ultrafast gradient echo MRA techniques with very short TR and TE have been developed. Although the precise sequence parameters vary between manufacturers, they are basically similar. The choice between performing a time-resolved or high spatial resolution CE-MRA examination depends upon the precise clinical application. The most common applications include the study of cerebral aneurysms, arteriovenous malformations, dural arteriovenous fistulas and dural venous diseases.
多项研究已表明,对比增强磁共振血管造影(CE-MRA)在主动脉弓上血管成像中具有实用性,因此它迅速成为一种常规成像方式。与非增强技术相比,其主要优势在于能够采集更大的容积,从而可显示从起源至颅内段的颈动脉。大多数已发表的关于颈动脉CE-MRA的研究都是使用T1弛豫率值相似的标准钆基螯合物进行的。最近,已研发出新型钆螯合物,如钆贝葡胺(Gd-BOP-TA,MultiHance;意大利米兰的Bracco Imaging公司),其血管内T1弛豫率值明显更高。当以与标准剂相同的剂量给药时,这些新型造影剂可产生显著更强的血管内信号增强。合适的高弛豫率造影剂的可用性也可能有助于克服一些影响颅内血管系统时间飞跃(TOF)和相位对比(PC)磁共振血管造影的内在技术问题(例如与血流相关的问题)。为避免静脉重叠问题,已开发出具有极短TR和TE的超快梯度回波MRA技术。尽管不同制造商的精确序列参数有所不同,但基本相似。进行时间分辨或高空间分辨率CE-MRA检查的选择取决于具体的临床应用。最常见的应用包括脑动脉瘤、动静脉畸形、硬脑膜动静脉瘘和硬脑膜静脉疾病的研究。